OCS

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trials Oculis will focus its developmental efforts and financial resources on the ongoing Privosegtor PIONEER registrational program in optic neuropathies and the Licaminlimab PREDICT-1 registrational trial in dry eye disease Financial position remains strong with $278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash runway into 2H 2029Conference call today at 4:30 pm ET ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in patients with diabetic macular edema (DME). The DIAMOND (DIAbetic Macular edema patients ON a Drop) program consisted of two Phase 3, double-masked, randomized, multi-center trials to evaluate the efficacy and safety of OCS-01 eye drops in patients with DME following 52 weeks of treatment. Over 800 patients were enrolled across both pivotal trials at 119 investigational sites throughout the United States and several other countries. The primary endpoint, mean change in best corrected visual acuity early treatment diabetic retinopathy study (BCVA ETDRS) letter score at Week 52, was not met in both trials. The secondary endpoint of retinal thickness, as measured by OCT, showed a substantial and persistent reduction with OCS-01 vs vehicle at all visits in DIAMOND-2 and at all visits except Week 52 in DIAMOND-1. The key secondary endpoint of the proportion of patients with ≥15-letter gain in BCVA was not met in both trials. OCS-01 was well tolerated, with no unexpected adverse events observed, and the overall safety profile was consistent with that of previous trials. Based on the results, at this time, Oculis does not plan to pursue an FDA regulatory filing for OCS-01 in DME. Riad Sherif, M.D., Chief Executive Officer of Oculis, said: “We are naturally disappointed that the substantial and sustained reduction in retinal thickness observe...

ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 12:00 p.m. CEST, including the election of Gregory D. Perry to its Board of Directors. 2026 Annual General Meeting Results The Company’s shareholders approved all agenda items. The shareholders approved the 2025 Annual Report including the 2025 Annual (Statutory) Financial Statements and the 2025 Consolidated Financial Statements. The shareholders acknowledged that on a standalone statutory financial statement basis, the Company incurred a loss of CHF 33,670,000 with respect to the financial year ended December 31, 2025, and resolved that the accumulated balance sheet loss of CHF 80,247,000 shall be carried forward to the new accounts. The members of the Board of Directors and the Executive Committee were granted discharge for their activities in 2025. Anthony Rosenberg was re-elected as member and chairperson of the Board of Directors. Christina Ackermann, Lionel Carnot, Arshad M. Khanani, Martijn Kleijwegt, Geraldine O’Keeffe, Riad Sherif and Robert K. Warner were re-elected as members of the Board of Directors. Gregory D. Perry was elected as a member of the Board of Directors. Lionel Carnot, Geraldine O'Keeffe and Gregory D. Perry were elected as members of the Compensation Committee. PricewaterhouseCoopers SA (Lausanne) was re-elected as Statutory Auditors. Blum & Partner AG (Zug) was elected as Independent Proxy. The shareholders approved the compensation for the non-executive members of the Board of Directors: Total maximum amount of fixed (non-performance-related) compensation for the non-executive members of the Board of Directors until the end of the Company’s 2027 Annual General Meeting: USD 572,000. Maximum value of equity or equity-based compensation for eight non-executive members of the Board of Directors until the end of the Company's 2027 Annual General Meeting: USD 2,150,000 (excluding employer social security and pension contributions). The shareholders approved the compensation for members of the Executive Committee: Total maximum amount of fixed (non-performance-related) compensation for three members of the Executive Committee for the calendar year 2027 and payable in 2027...

Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026 Licaminlimab PREDICT-1 Trial in Active Site Recruitment Phase, Pioneering a Genotype-Driven Path to Precision Medicine in Dry Eye Disease Privosegtor Regulatory Path Cleared via FDA SPA; PIONEER-1 Phase 3 Trial Advances with Ongoing Site Activation Cash, cash equivalents, and short-term investments of $277.6 million as of March 31, 2026, providing cash runway into 2H 2029 ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the first quarter ended March 31, 2026, and provided an overview of the Company’s progress. Riad Sherif, M.D., Chief Executive Officer of Oculis, stated, “We began 2026 with strong execution momentum across our late-stage clinical trials. We are positioned for a pivotal year, with key readouts for OCS-01 in diabetic macular edema (DME) expected in June and Licaminlimab in dry eye disease (DED) around year-end, while the Privosegtor PIONEER program is making significant progress, including PRIME designation in Europe and an agreement with the FDA on the Special Protocol Assessment (SPA) regarding PIONEER-1 and ongoing centers activation. Driven by a mission to restore vision, we are targeting global market opportunities exceeding $30 billion.” Recent Development Highlights and Upcoming Milestones: OCS-01: Last patient last visit (LPLV) completed in the DIAMOND (DIAbetic Macular edema patients ON a Drop) program, consisting of two Phase 3, double-masked, randomized, multi-center trials to evaluate the efficacy and safety of OCS-01 eye drops in patients with DME following 52-weeks of treatment. Topline results are expected to readout in June 2026, and, if positive, an NDA submission to the FDA is planned for Q4 2026. The DME AWARE Delphi study results were recently presented at the 17th annual congress on Controversies in Ophthalmology (COPHy) and at the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting. In this study, supported by Oculis, 25 leading global retina and ophthalmology experts were surveyed to establish consensus on un...

This article first appeared on GuruFocus. Oculis Holding AG (NASDAQ:OCS) is set to release its Q1 2026 earnings on May 7, 2026. The consensus estimate for Q1 2026 revenue is $0.27 million, and the earnings are expected to come in at -$0.52 per share. The full year 2026's revenue is expected to be $8.60 million and the earnings are expected to be -$2.21 per share. More detailed estimate data can be found on the Forecast page. Warning! GuruFocus has detected 2 Warning Sign with OCS. Is OCS fairly valued? Test your thesis with our free DCF calculator. Revenue estimates for Oculis Holding AG (NASDAQ:OCS) have increased from $7.87 million to $8.60 million for the full year 2026 and declined from $78.17 million to $49.93 million for 2027 over the past 90 days. Earnings estimates for Oculis Holding AG (NASDAQ:OCS) have increased from -$2.40 per share to -$2.21 per share for the full year 2026 and increased from -$2.61 per share to -$2.35 per share for 2027 over the past 90 days. In the previous quarter of 2025-12-31, Oculis Holding AG's (NASDAQ:OCS) actual revenue was $0.53 million, which beat analysts' revenue expectations of $0.17 million by 214.97%. Oculis Holding AG's (NASDAQ:OCS) actual earnings were -$0.54 per share, which met analysts' earnings expectations. After releasing the results, Oculis Holding AG (NASDAQ:OCS) was down by -3.64% in one day. Based on the one-year price targets offered by 10 analysts, the average target price for Oculis Holding AG (NASDAQ:OCS) is $47.79 with a high estimate of $55.69 and a low estimate of $38.47. The average target implies an upside of 69.52% from the current price of $28.19. Based on GuruFocus estimates, the estimated GF Value for Oculis Holding AG (NASDAQ:OCS) in one year is $0, suggesting a downside of -100% from the current price of $28.19. Based on the consensus recommendation from 11 brokerage firms, Oculis Holding AG's (NASDAQ:OCS) average brokerage recommendation is currently 1.5, indicating a "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

TG Therapeutics (TGTX) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -26.88%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.35 per share when it actually produced earnings of $0.14, delivering a surprise of -60%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. TG Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $204.92 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 2.81%. This compares to year-ago revenues of $120.86 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. TG Therapeutics shares have added about 21.1% since the beginning of the year versus the S&P 500's gain of 6%. While TG Therapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for TG Therapeutics was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the c...

ZUG, Switzerland, March 03, 2026 (GLOBE NEWSWIRE) -- Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) in Q2 2026 Key expansion in neuro-ophthalmology with Breakthrough Therapy designation granted to Privosegtor, propelling the PIONEER registrational program in optic neuropathies with a potential U.S. market opportunity of over $7 billion Cash, cash equivalents, and short-term investments of $268.7 million as of December 31, 2025, providing cash runway into 2029 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the fourth quarter and full year ended December 31, 2025, and provided an overview of the Company’s progress. Riad Sherif, M.D., Chief Executive Officer of Oculis, stated “Oculis has delivered a transformative 2025, marked by significant clinical progress across our late-stage portfolio and a strategic expansion into neuro-ophthalmology. The compelling Phase 2 ACUITY results for Privosegtor in optic neuritis led to a pivotal FDA Breakthrough Therapy designation and anchored the launch of our global PIONEER registrational program. We believe Privosegtor holds immense potential as a first-in-class neuroprotective platform for a range of neuro-axonal diseases. 2026 is positioned to be a landmark year for the company with a roadmap featuring three major expected registrational milestones: the DIAMOND-1 and DIAMOND-2 trials readout with OCS-01, a potential first-in-class eye drop in DME, anticipated in Q2, the PREDICT-1 trial results for Licaminlimab with a precision medicine approach in dry eye disease planned in Q4, and the commencement of three registrational trials with Privosegtor as part of the PIONEER program. The operational excellence and significant milestones we achieved in 2025 have uniquely positioned Oculis to drive innovation in areas of high unmet medical need, a potential market opportunity of over $30 billion, with the aim of redefining the standard of care in ophthalmology and neuro-ophthalmology.” Recent Clinical Highlights and Upcoming Milestones: Privosegtor: Break...

This article first appeared on GuruFocus. Oculis Holding AG (NASDAQ:OCS) is set to release its Q4 2025 earnings on March 3, 2026. The consensus estimate for Q4 2025 revenue is $0.17 million, and the earnings are expected to come in at -$0.55 per share. The full year 2025's revenue is expected to be $1.01 million and the earnings are expected to be -$2.49 per share. More detailed estimate data can be found on the Forecast page. Warning! GuruFocus has detected 2 Warning Sign with OCS. Is OCS fairly valued? Test your thesis with our free DCF calculator. Over the past 90 days, revenue estimates for Oculis Holding AG (NASDAQ:OCS) have declined from $1.13 million to $1.01 million for the full year 2025, and from $10.10 million to $8.00 million for 2026. During the same period, earnings estimates have increased from -$2.51 per share to -$2.49 per share for 2025, and from -$2.54 per share to -$2.44 per share for 2026. In the previous quarter ending on September 30, 2025, Oculis Holding AG's (NASDAQ:OCS) actual revenue was $0.32 million, which beat analysts' revenue expectations of $0.25 million by 27.94%. Oculis Holding AG's (NASDAQ:OCS) actual earnings were -$0.42 per share, which beat analysts' earnings expectations of -$0.54 per share by 22.39%. After releasing the results, Oculis Holding AG (NASDAQ:OCS) was up by 0.41% in one day. Based on the one-year price targets offered by 10 analysts, the average target price for Oculis Holding AG (NASDAQ:OCS) is $44.22, with a high estimate of $55.28 and a low estimate of $29.15. The average target implies an upside of 50.88% from the current price of $29.31. Based on GuruFocus estimates, the estimated GF Value for Oculis Holding AG (NASDAQ:OCS) in one year is $0, suggesting a downside of -100% from the current price of $29.31. Based on the consensus recommendation from 11 brokerage firms, Oculis Holding AG's (NASDAQ:OCS) average brokerage recommendation is currently 1.5, indicating a "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) following positive FDA meeting OCS-01 DIAMOND Phase 3 trials in diabetic macular edema (DME) remain on track for topline results expected in Q2 2026 Licaminlimab PREDICT-1 registrational trial, the first genotype-based trial to drive precision medicine in dry eye disease (DED), expected to start in Q4 2025 Cash, cash equivalents and short-term investments of $182.2 million as of September 30, 2025 plus recent $110 million financing, extend cash runway into 2029 ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the third quarter ended September 30, 2025, and provided an overview of the Company’s progress. Riad Sherif, M.D., Chief Executive Officer of Oculis, stated: “Oculis has entered a pivotal stage in its transformation into a leader in ophthalmology and neuro-ophthalmology, powered by its differentiated and innovative portfolio. We are excited about several key developments: OCS-01 eye drops Phase 3 in DME with anticipated readout in Q2 2026, the initiation of a first in class registrational trial with Licaminlimab in precision medicine for DED, and, very importantly, we are thrilled with our positive discussions with the U.S. Food and Drug Administration (FDA), which paved the way to accelerate Privosegtor development in key unmet medical needs. Our recent financing now secures the resources needed for three pivotal trials in optic neuropathies, a potential market opportunity representing approximately $7 billion in the U.S. alone, with no available therapies. Supported by a strong balance sheet and a robust late-stage pipeline, we are well-positioned to achieve 6 pivotal readouts with the current funding, reinforcing our commitment to delivering groundbreaking treatments.” Recent Clinical Highlights and Upcoming Milestones: Privosegtor: Following a successful meeting with the FDA, Oculis announced the launch of the PIONEER program, which will include three pivotal trials to support registration plans for Privosegtor in AON and...

This article first appeared on GuruFocus. Oculis Holding AG (NASDAQ:OCS) is set to release its Q3 2025 earnings on Nov 6, 2025. The consensus estimate for Q3 2025 revenue is $0.23 million, and the earnings are expected to come in at -$0.51 per share. The full year 2025's revenue is expected to be $1.11 million and the earnings are expected to be -$2.48 per share. More detailed estimate data can be found on the Forecast page. Warning! GuruFocus has detected 1 Warning Sign with OCS. Is OCS fairly valued? Test your thesis with our free DCF calculator. Revenue estimates for Oculis Holding AG (NASDAQ:OCS) have increased from $0.97 million to $1.11 million for the full year 2025. However, they have declined from $17.63 million to $12.75 million for 2026 over the past 90 days. Earnings estimates have declined from -$2.41 per share to -$2.48 per share for the full year 2025 and from -$2.55 per share to -$2.60 per share for 2026 over the same period. In the previous quarter of 2025-06-30, Oculis Holding AG's (NASDAQ:OCS) actual revenue was $0.32 million, which beat analysts' revenue expectations of $0.23 million by 40.61%. Oculis Holding AG's (NASDAQ:OCS) actual earnings were -$0.61 per share, which missed analysts' earnings expectations of -$0.57 per share by -5.77%. After releasing the results, Oculis Holding AG (NASDAQ:OCS) was up by 1.42% in one day. Based on the one-year price targets offered by 7 analysts, the average target price for Oculis Holding AG (NASDAQ:OCS) is $40.08, with a high estimate of $49.40 and a low estimate of $29.64. The average target implies an upside of 107.91% from the current price of $19.28. Based on GuruFocus estimates, the estimated GF Value for Oculis Holding AG (NASDAQ:OCS) in one year is $0, suggesting a downside of -100% from the current price of $19.28. Based on the consensus recommendation from 9 brokerage firms, Oculis Holding AG's (NASDAQ:OCS) average brokerage recommendation is currently 1.4, indicating a "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies strong buy, and 5 denotes sell.

ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the upcoming presentation of the positive Phase 2 ACUITY trial results investigating Privosegtor (OCS-05) in acute optic neuritis at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Congress. Details of Oculis’ presentation: ECTRIMS 2025: Reduction in Retinal Ganglion Cell Loss and Improved Low Contrast Visual Acuity with Privosegtor in Acute Optic Neuritis: Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial. Presenter: Céline Louapre, M.D., Ph.D., Pitié-Salpêtrière Hospital Session: Late Breaking Abstracts Date/Time: Wednesday, September 24, 2025; 08:30 CET Riad Sherif, M.D., Chief Executive Officer of Oculis, commented: “It is a privilege to collaborate with Pitié-Salpêtrière Hospital, a world-renowned center for modern neurology, on the Phase 2 ACUITY trial investigating Privosegtor (OCS-05) in patients with acute optic neuritis, a well-established clinical model for neuroprotection. Topline results showed clinically meaningful improvements in vision with 18 letters at 3 months, along with the preservation of retinal structure and a favorable safety profile, highlighting Privosegtor’s potential broad applicability in various neuro-ophthalmic and neurological diseases. We look forward to sharing these significant results with the multiple sclerosis community as we continue to advance this candidate into further studies in optic neuritis and beyond, including a new program to be initiated for the treatment of MS relapses.” Céline Louapre, M.D., Ph.D., added: “It is an honor to present these positive results at ECTRIMS, the largest MS congress in the world. In this study, Privosegtor (OCS-05) demonstrated promising neuroprotective effects, including the preservation of retinal ganglion cells, and was also associated with significant improvements in low contrast visual acuity. With acute optic neuritis often manifesting as the first sign of multiple sclero...

ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in diabetic macular edema (DME) to be presented Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations at the Ophthalmology Futures Retina Forum, the EURETINA Innovation Spotlight (EIS), the 25th European Society of Retina Specialists (EURETINA) Congress, and the Retina Society Annual Congress. Oculis will present clinical trial results from its innovative late-stage pipeline, including expanded data analyses from Stage 1 of the Phase 3 DIAMOND program on subgroups by lens status and prior treatment status. The results highlight the potential of OCS-01 to benefit various DME patient profiles, including phakic and pseudophakic patients, as well as treatment naïve and previously treated patients. Data from the Phase 2 ACUITY trial investigating Privosegtor (OCS-05), a potential neuroprotective therapy for acute optic neuritis, will be presented during the late-breaking session at the 25th EURETINA Congress. Previously disclosed headline results from the trial showed clinically meaningful visual function improvement with anatomical neuroprotection benefits in patients treated with Privosegtor, suggesting potential applicability in multiple retinal, neuro-ophthalmological and neurological conditions. Additionally, the winner of the annual Ramin Tadayoni Award will be announced during the EURETINA opening ceremony on September 4, 2025. Established by EURETINA in partnership with Oculis, the award honors the legacy of Professor Tadayoni, Oculis’ former Chief Scientific Officer and a renowned retina specialist. This prestigious award promotes innovative research by recognizing an outstanding postgraduate scholar with the potential to make significant advances in understanding and treating retinal diseases. Details of Oculis’ presentations are as follows: Ophthalmology Futures Retina Forum: Is Diabetic Retinopathy the Overlooked Elephant in the Room – Panel Discussion Presenter: Riad Sherif, M.D., Chief Executive Officer Date/Time:...

Net loss: CHF25.4m (loss widened by 22% from 2Q 2024). CHF0.48 loss per share. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 71%. Earnings per share (EPS) missed analyst estimates by 8.5%. Looking ahead, revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's shares are down 1.2% from a week ago. Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Oculis Holding (1 is significant) you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.